Regeneron teams up with Telix in a 50/50 radiopharma deal, betting on next-gen cancer therapies to expand its oncology pipeline and long-term growth.
The taxpayer-funded outreach organisation JCP Youth runs the "flagship" BEAST program to divert at-risk youths, but a ...